DETECTION OF AUTOANTIBODIES AND ALLOANTIBODIES AGAINST PLATELET-ASSOCIATED ANIGENS
Although autoantibodies against the platelet glycoproteins (GP) and a 1loantibodies toward class I HLA antigens have been demonstrated using various methods, practical techniques for their detection have not been available.We studied 59 patients with chronic immune thrombocytopenic purpura (ITP) where platelet-associated and plasma autoantibodies against the GP Ilb/IIIa complex and GP lb were measured using a newly developed imraunobead assay and a previously described microtiter well assay. The specificity of both assays depends on the monoclonal antibody employed (e.g., GPIIb/IIIa, lb or HLA). Platelet-associated autoantibody was detected using the immunobead assay in 21 of 28 patients (13 with anti-GPIIb/IIIa and 8 with anti-GPIb). Plasma autoantibodies were noted in 34 of 59 patients (21 with anti-GPIIb/IIIa, 11 with anti-GPIb and 2 with both). Positive results were noted in 30 of 59 ITP patients using the immunobead assay and in only 14 of 59 using the microtiter well assay, suggesting that solubilization prior to antibody addition, as in the microtiter well assay, alters epitope stability. However, the microtiter well assay appears to define a poor prognostic group. Of 11 patients with positive well assays who underwent splenectomy, only one achieved a complete remission, 3 have died and all require continuous high-dose steroids or immunosuppressants. Of the 31 thrombocytopenic controls studied, all gave negative results using both assays.The immunobead assay was adapted to specifically measure anti-HLA antibodies and was used to evaluate 51 single donor platelet transfusions given to 7 patients refractory to random platelets. Twenty-nine of 33 (88%) transfusions associated with a negative assay had successful outcomes (1 hr increment >7500) while only 2 of 18 (11.1%) episodes associated with a positive test had successful outcomes. Only 1 unsuccessful transfusion episode was associated with a negative immunobead and a positive antiglobulin test suggesting that transfusion-related alloantibodies, other than to class I HLA antigens, are an uncommon cause of refractoriness.We conclude that these two clinically adaptable assays are capable of measuring both autoantibodies and anti-HLA alloantibodies with a high degree of sensitivity.